Evidence map›Paper›PMID 40948524›Full record

ArticleAmerican journal of cancer research2025

Clinical characteristics and prognostic value of serological markers in pancreatic neuroendocrine tumors: a single-center retrospective study.

Renrui Wan, Junfeng Wang, Ping Xie, Xiaochang Wu, Kun Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Renrui WanDepartment of Hepatobiliary Surgery, Huzhou Central Hospital (The Affiliated Central Hospital of Huzhou Teachers College, The Fifth School of Clinical Medicine, Zhejiang Chinese Medical University, The Affiliated Huzhou Hospital, Zhejiang University School of Medicine) Huzhou 313000, Zhejiang, P. R. China.
Junfeng WangDepartment of Hepatobiliary Surgery, The Fourth Affiliated Hospital of Zhejiang University School of Medicine Yiwu 322000, Zhejiang, P. R. China.
Ping XieDepartment of Hepatobiliary Surgery, Huzhou Central Hospital (The Affiliated Central Hospital of Huzhou Teachers College, The Fifth School of Clinical Medicine, Zhejiang Chinese Medical University, The Affiliated Huzhou Hospital, Zhejiang University School of Medicine) Huzhou 313000, Zhejiang, P. R. China.
Xiaochang WuDepartment of Hepatobiliary Surgery, Huzhou Central Hospital (The Affiliated Central Hospital of Huzhou Teachers College, The Fifth School of Clinical Medicine, Zhejiang Chinese Medical University, The Affiliated Huzhou Hospital, Zhejiang University School of Medicine) Huzhou 313000, Zhejiang, P. R. China.
Kun GuoDepartment of General Surgery, Huzhou Central Hospital (The Affiliated Central Hospital of Huzhou Teachers College, The Fifth School of Clinical Medicine, Zhejiang Chinese Medical University, The Affiliated Huzhou Hospital, Zhejiang University School of Medicine) Huzhou 313000, Zhejiang, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the clinical characteristics, diagnostic methods, treatment strategies and prognostic factors of pancreatic neuroendocrine tumors (pNETs).

methodsA retrospective analysis was conducted on 43 pNET patients treated at Huzhou Central Hospital from January 2003 to December 2023. The data included age, gender, function, tumor location, tumor size, pathological characteristics, lymph nodes, metastasis, and treatment. Association of these factors with pNET prognosis was proven by univariate analysis and multivariate analysis.

resultsThe incidence of G3 tumors in this group of advanced patients was relatively high (P=0.001). Meanwhile, elevated CA125 was commonly seen in the advanced stage (P=0.045), and surgeries occurred more frequently in the early stage (P=0.003). In addition, the positive expression of CD56 in low-grade tumors was relatively high (P=0.014). The incidence of non-functional tumors larger than 2 cm was high (P=0.015). Univariate Cox regression revealed that tumor size >2 cm, G3 grade, liver metastasis, advanced stage, lymph node metastasis and invasion were risk factors. Multivariate analysis revealed that G3 grade, liver metastasis and advanced stage were independent influencing factors for disease progression.

conclusionpNETs are heterogeneous tumors. Pathological grade, metastatic status, and serological markers may assist in diagnosis and prognosis assessment, aiding individualized clinical management.

Indexed as

clinical and pathological featuresdiagnosisPancreatic neuroendocrine tumorsprognostic analysistreatment

Identifiers

PMID40948524
PMCPMC12432554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.